Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.73 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.73 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.71 |
| ▸ | TNF | P01375 | 1/20 | 0.71 |
| ▸ | IL1B | P01584 | 1/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.71 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053208 | 1.00 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL6179000 | 1.00 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24922300 | 0.92 | DDB1 (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22787058 | 0.90 | CRBN (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26372292 | 0.90 | DDB1 (0.66) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23589806 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23768364 | 0.89 | CRBN (0.72) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25270736 | 0.89 | CRBN (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29922269 | 0.89 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL5635300 | 0.89 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4695259-B2 | — | — | 2011-06-08 | — | — | JP | claimed |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2008-11-20 | — | — | US | claimed |
| EP-1064277-B1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | CELGENE CORP (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1357120-A1 | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | CELGENE CORPORATION (US) | 2003-10-29 | — | — | EP | claimed |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2003-02-06 | — | — | US | claimed |
| US-6403613-B1 | ANTI-INFLAMMATORY AGENT THAT REDUCES LEVELS OF CYTOKINES (INCLUDING TUMOR NECROSIS FACTOR) | CELGENE CORPORATION | 2002-06-11 | — | — | US | claimed |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | MAN HON-WAH (US) | 2001-07-05 | — | — | US | claimed |
| EP-1064277-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | Gelgene Corporation (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999047512-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | COLGENE CORPORATION (US) | 1999-09-23 | — | — | WO | claimed |
| WO-2024006403-A2 | SELECTIVE HISTONE DEACETYLASE 8 (HDAC8) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11839659-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein | NORTHWESTERN UNIVERSITY (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2023220722-A2 | PAK1 DEGRADERS AND METHODS OF USE THEREOF | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
| EP-1357120-A1 | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | CELGENE CORPORATION (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2003-02-06 | — | — | US | disclosed |
| US-6403613-B1 | ANTI-INFLAMMATORY AGENT THAT REDUCES LEVELS OF CYTOKINES (INCLUDING TUMOR NECROSIS FACTOR) | CELGENE CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | MAN HON-WAH (US) | 2001-07-05 | — | — | US | disclosed |
| EP-1064277-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | Gelgene Corporation (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047512-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | COLGENE CORPORATION (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839659-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein | IDO1, IDO2, KMO | DDB1 1197/4885CRBN 176/4885IKZF3 151/4885 |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | IL1A, IL1B, TNF | DDB1 621/4885CRBN 4056/4885IKZF3 275/4885 |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | TNF, IL1A, IL1B | DDB1 733/4885CRBN 4134/4885IKZF3 275/4885 |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | TNF, IL1A, IL1B | DDB1 733/4885CRBN 4134/4885IKZF3 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.